Dermsquared Scheduled Maintenance, Thursday Feb 29, 6:30am to 8:30am EST

Live Evaluations

Therapeutic Options in Vitiligo Treatment: An Evolving Landscape

About

Therapeutic Options in Vitiligo Treatment: An Evolving Landscape

This activity is supported by an educational grant from Incyte.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Describe the role of emerging therapies for the treatment and management of vitiligo.

  • Describe strategies to individualize care when using emerging therapies for vitiligo.

  • Identify techniques for incorporating emerging vitiligo therapies into everyday practice.

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Andrew
Andrew Alexis, MD, MPH

Vice-Chair for Diversity and Inclusion, Dept. of Dermatology
Professor of Clinical Dermatology 
Weill Cornell Medicine
New York, NY

Seemal
Seemal Desai, MD

Clinical Assistant Professor
Department of Dermatology
University of Texas Southwestern Medical Center
Dallas, TX

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Andrew F. Alexis, MD, MPH

Grant/Research Support: BMS, LEO, Novartis, Almirall

Consultant: Leo, Galderma, Pfizer, Sanofi- Regeneron

Speakers’ Bureau or Honoraria: Regeneron, SANOFI-Genzyme, Pfizer, BMS

Seemal R. Desai, MD

Grant/Research Support: AbbVie, Incyte, Dermavant, AOBiome,

Consultant: Galderma, Almirall, Ferndale, BMS, AbbVie, Verrica, UCB, Ortho, Scientis, EPI, Avita, Eli Lilly, Leo, Pfizer, Incyte, L’Oreal, Beiersdorf, J&J

Speakers’ Bureau or Honoraria: Dermavant, Galderma, Pfizer

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved